1. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial
- Author
-
L. Kvill, S. Ball, R. Harrington, Jack E. Smith, A. Kristinsson, David J. Moliterno, James E. Tcheng, D. Marcantuono, M. Goeres, Stephen G. Ellis, K. Finnie, T. Nygaard, M. Senaratne, G. Carreon, John F. Seaworth, Manjushri Bhapkar, John H. Alexander, J. Diodati, Kathleen M. Trollinger, E. Luiden, Cynthia Binanay, D. Debowey, G. Strand, A. Rames, M. Dorsey, A. Prosser, F. Van de Werf, J. Becker, C. Morgan, N. Kohler, K. Tinnin, Lee W. Jones, K. Andreatta, S. McCreery, N. Bhalodkar, P. Greenwood, T. Ivanc, B. Spinogatti, A. Paraschos, B. Steiner, Cynthia L. Green, S. Roth, S. Nallcy, N. McIntosh-Yellin, Brian S. Crenshaw, W. Hui, A. Valeria, M. Edwards, William B. Hillegass, M. Peek, E. Shalit, Barbara E. Tardiff, A. B. Chandler, Mitchell W. Krucoff, J. Jensen, H. Plardardottir, Richard C. Becker, A. Michael Lincoff, J. K. White, Joseph A. Puma, T. Nielsen, L. Paraschos, K. Feskiw, G. Oddsson, Eric J. Topol, V. Runarsdottir, Robert A. Harrington, Keith H. Newby, B. Potkin, K. Quintero, P. Desantis, Eric R. Bates, A. Luyten, K. Lerrick, John M. Burks, W. Sutherland, T. Johnson, J. Parker, Robert M. Califf, Paul W. Armstrong, James P. White, and M. Bokslag
- Subjects
Adult ,Male ,Platelet Aggregation ,Platelet aggregation ,medicine.drug_class ,medicine.medical_treatment ,Myocardial Infarction ,Acetates ,Pharmacology ,Double-Blind Method ,medicine ,Humans ,Thrombolytic Therapy ,Myocardial infarction ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Fibrinolysis ,Thrombolysis ,Middle Aged ,Receptor antagonist ,medicine.disease ,Platelet glycoprotein IIb-IIIa ,Treatment Outcome ,Tyrosine ,Female ,Medical emergency ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors - Abstract
The trial was designed to assess the safety, pharmacodynamics and effects on reperfusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor lamifiban when given with thrombolysis to patients with ST segment elevation acute myocardial infarction.Studies of fibrinolytic agents in acute myocardial infarction have demonstrated a direct relationship between early complete reperfusion and survival. Blockade of the platelet GP IIb/IIIa receptor complex inhibits platelet aggregation and may speed reperfusion when given in conjunction with thrombolysis to patients with acute myocardial infarction.Patients with ST segment elevation presenting within 12 h of symptom onset who were treated with either tissue-plasminogen activator or streptokinase were enrolled in this three-part Phase II dose exploration study. In Part A, all patients received the GP IIb/IIIa inhibitor lamifiban in an open-label, dose escalation scheme. Parts B and C were a randomized, double-blind comparison of a bolus plus 24-h infusion of lamifiban versus placebo with patients randomized in a 2:1 ratio. The goal was to identify a dose(s) of lamifiban that provided85% adenosine diphosphate (ADP)-induced platelet aggregation inhibition. A composite of angiographic, continuous electrocardiographic and clinical markers of reperfusion was the primary efficacy end point, and bleeding was the primary safety end point.Platelet aggregation was inhibited by lamifiban in a dose-dependent manner with the highest doses exceeding 85% ADP-induced platelet aggregation inhibition. There was more bleeding associated with lamifiban (transfusions in 16.1% lamifiban-treated vs. 10.3% placebo-treated patients). Lamifiban induced more rapid reperfusion as measured by all continuous electrocardiographic (ECG) parameters.Lamifiban given with thrombolytic therapy appears to be associated with more rapid and complete reperfusion than placebo. As expected in this small sample, there were no obvious clinical benefits to lamifiban over placebo. Reconciliation of ECG monitoring with clinical outcomes will require a larger, adequately powered clinical trial.
- Published
- 1998
- Full Text
- View/download PDF